Clinical Trial Search

Primary: Safety: Time to Reach a 4 Point Increase (Worsening) in Unified Parkinson's Disease Rating Scale (UPDRS) Motor Score — 15; 14.1 months — p=0.968

Primary: Change in Free-water Accumulation in the Substantia Nigra — 0.0009; 0.0041 arbitrary units (A.U.s)

Primary: L-DOPA Insensitivity — 5 Participants — p=0.00468

Primary: Unified Parkinson's Disease Rating Scale (UPDRS) II (Activities of Daily Living) Score: Mean Change From Baseline to 12 Months After Hospital Discharge — -2.1; 1.4 units…

Primary: Unified Parkinson Disease Rating Scale (UPDRS). — 12; 12; 10; 10 units on a scale

Primary: Change From Baseline in Mean "Off" Time — -0.9; -0.9; -0.8; -0.8 Hours/day — p=0.8700

Primary: Number of Subjects With at Least One Adverse Event During This Open-label Extension Study — 258 Subjects

Primary: Change in Gait Capacity as Assessed b 6-Minute Walk Test — 235.7; 150.0 Feet

Primary: Change From Baseline (BL) in Total Awake Time Spent "Off" at Week 4 of Maintenance Period — -1.91; -2.04; -2.92; -2.34 Hours — p=0.814

Primary: Change From Baseline to the End of the Maintenance Period in Pain Severity Assessed Using an 11-point Likert Pain Scale — -2.2; -2.8 scores on a scale — p=0.172

Primary: Change in Dopamine Transporter Imaging — 4.6; -15.9 % change in arbitrary intensity units

Primary: Change From Baseline to Week 12 of the Double-Blind Treatment Period in Average Daily Normalized "On" Time Without Troublesome Dyskinesia — 0.97; 2.72 hours — p=0.0083

Primary: Change in MDS-UPDRS Part III Motor (OFF) Score — 0.44; -2.96 score on scale — p=>0.05

Primary: Change From Baseline to Endpoint of 12 Weeks in the 3-day Average of Awake Time Per Day Spent in the "Off" State — -0.4; -1.3; -1.6; -1.7 hours/day — p=0.753

Primary: Reaction Time and Variability for Movement Task — 1013.858333; 994.94875; 979.2450877; 910.9120833 milliseconds

Primary: Change in Patient Quality of Life as Measured by the EuroQol 5-D (EQ-5D) Scale Between Baseline (Visit 1) and 1 Year (Visit 4) — 1; 0.5; 0.5; 0 units on a scale — p=0.59

Primary: Change in Bangor Goal Setting Interview (BGSI) Goal Attainment — 4.5; 4.6; 5.9; 7.4 score on a scale

Primary: Change in Total Unified Parkinson's Disease Rating Scale (UPDRS) Score From Baseline to 44 Weeks — 4.42; 5.13; 6.25 units on a scale

Primary: Clinical Global Impression (CGI) Item 4 (Side Effects) at the End of the Treatment Period — 61; 22; 3; 3 participants

Primary: TST — 5.7; 6.0 hours

Primary: Change From Baseline to the End of the Maintenance Period in the Score of the Apathy Evaluation Scale (AS) Rated by the Patient — -4.4; -4.6; -4.9 scores on a scale…

Primary: Number of Subjects With at Least One Adverse Event During This Open-label Extension Study — 357 Subjects

Primary: Alzheimer's Disease Cooperative Study- Clinical Global Impression Change (ADCS-CGIC) — 3.92; 3.48 scores on the CGIC

Primary: Hamilton Depression Rating Scale: Baseline — 20.93; 19.38 units on a scale

Primary: Number of Participants With Treatment-Emergent Adverse Events [Safety & Tolerability] — 1 Participants

Primary: (Aim 1) Mean of User Acceptance Questionnaire (UAQ) Part 1 Total Scores — 7.28 score on a scale

Primary: AChE PET Neuroimaging — 0.0238; 0.0226 1/min — p=0.0009

Primary: Change in Daily "OFF" Time — -2.8; -1.3 Hours

Primary: Change From Baseline to Week 16 in Modified Functional Status Questionnaire (mFSQ) Total Score — 14.0 score on a scale — p=<0.0001

Primary: Unified Parkinson's Disease Rating Scale (UPDRS) Part 3 Sum Score — -10.1; -4.4 Scores on a scale